A Phase II Study of Avelumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 21 Feb 2018 Planned End Date changed from 1 Dec 2019 to 31 Dec 2021.
- 21 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2020.
- 09 Jan 2018 Status changed from not yet recruiting to recruiting.